<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="196195">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00537056</url>
  </required_header>
  <id_info>
    <org_study_id>RENAL0013</org_study_id>
    <secondary_id>97807</secondary_id>
    <secondary_id>RENAL0013</secondary_id>
    <secondary_id>8558</secondary_id>
    <nct_id>NCT00537056</nct_id>
  </id_info>
  <brief_title>Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI</brief_title>
  <official_title>Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Comprehensive Cancer Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To learn whether FDG PET/CT and DCE MRI are better predictors of response to therapy than
      the current standard of care (CT or MRI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>histopathology</measure>
    <time_frame>clinical outcome usually prior to beginning on the trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>degree of tumor necrosis</measure>
    <time_frame>pre and post ( 12 weeks ) sutent therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor size</measure>
    <time_frame>pre and post ( 12 weeks ) sutent therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PET/CT (tumor size - FDG uptake)</measure>
    <time_frame>pre and post ( 12 weeks ) sutent therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI (tumor size)</measure>
    <time_frame>pre and post ( 12 weeks ) sutent therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>DCE MRI (AUC - peak flow)</measure>
    <time_frame>pre and post ( 12 weeks ) sutent therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>initial imaging tumor size</measure>
    <time_frame>pre sutent therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>noted on imaging days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>initial metabolic panel measures</measure>
    <time_frame>prior to baseline MRI</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Kidney Neoplasms</condition>
  <condition>Carcinoma, Renal Cell</condition>
  <condition>Kidney (Renal Cell) Cancer</condition>
  <arm_group>
    <arm_group_label>F-18 FDG PET/CT and DCE MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDG PET CT F-18 Fluoro-deoxi-glucose: 15 mCi iv Gadolinium-DTPA: 0.1 mmol/kg Sunitinib: 50 mg/day po</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FDG PET CT</intervention_name>
    <description>nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body</description>
    <arm_group_label>F-18 FDG PET/CT and DCE MRI</arm_group_label>
    <other_name>Positron emission tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DCE MRI</intervention_name>
    <description>DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).</description>
    <arm_group_label>F-18 FDG PET/CT and DCE MRI</arm_group_label>
    <other_name>Magnetic Resoning Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F-18 Fluoro-deoxi-glucose</intervention_name>
    <description>15 mCi iv</description>
    <arm_group_label>F-18 FDG PET/CT and DCE MRI</arm_group_label>
    <other_name>fluorodeoxyglucose (18F)</other_name>
    <other_name>Fludeoxyglucose (18F)</other_name>
    <other_name>18F-FDG</other_name>
    <other_name>FDG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadolinium-DTPA</intervention_name>
    <description>0.1 mmol/kg iv</description>
    <arm_group_label>F-18 FDG PET/CT and DCE MRI</arm_group_label>
    <other_name>Gadopentetic acid</other_name>
    <other_name>gadopentetate dimeglumine</other_name>
    <other_name>Gd-DTPA</other_name>
    <other_name>Berlex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>50 mg/day po</description>
    <arm_group_label>F-18 FDG PET/CT and DCE MRI</arm_group_label>
    <other_name>Sutent</other_name>
    <other_name>SU11248</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:- Measurable disease by RECIST criteria

          -  Pathologic diagnosis of renal cell cancer

          -  Advanced (stage IV) renal cell cancer

          -  Karnofsky performance status of (KPS&gt;70)

          -  Consent to participate in the clinical trial

        Exclusion Criteria:- Patients who cannot complete a PET/CT scan.

          -  Pregnant women.

          -  Healthy volunteers.

          -  Patients participating in other research protocols will be excluded from this study.

          -  Metallic implants (prosthesis, ICD, pacemakers), since these are contraindications
             for MRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Andrew Quon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 4, 2013</lastchanged_date>
  <firstreceived_date>September 26, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
